Two Sigma Investments
FDMT icon

Two Sigma Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Two Sigma Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
124,317
-213,186
-63% -$1.86M ﹤0.01% 3153
2025
Q4 		$2.53M Buy
337,503
+64,007
+23% +$649K ﹤0.01% 2271
2025
Q3 		$2.38M Sell
273,496
-257,667
-49% -$1.54M ﹤0.01% 2017
2025
Q2 		$1.97M Buy
531,163
+69,706
+15% +$245K ﹤0.01% 1842
2025
Q1 		$1.49M Buy
461,457
+147,464
+47% +$695K ﹤0.01% 1927
2024
Q4 		$1.75M Buy
313,993
+208,021
+196% +$1.63M ﹤0.01% 1808
2024
Q3 		$1.15M Buy
105,972
+78,449
+285% +$1.3M ﹤0.01% 2046
2024
Q2 		$578K Sell
27,523
-3,878
-12% -$97.3K ﹤0.01% 2303
2024
Q1 		$1M Buy
+31,401
New +$801K ﹤0.01% 1959
2023
Q4 		– Sell
-101,863
Closed -$1.3M – 3218
2023
Q3 		$1.3M Sell
101,863
-83,276
-45% -$1.39M ﹤0.01% 1786
2023
Q2 		$3.35M Sell
185,139
-15,744
-8% -$290K 0.01% 1127
2023
Q1 		$3.45M Buy
200,883
+46,909
+30% +$912K 0.01% 1078
2022
Q4 		$3.42M Buy
153,974
+137,525
+836% +$2.12M 0.01% 1049
2022
Q3 		$132K Sell
16,449
-29,546
-64% -$268K ﹤0.01% 2190
2022
Q2 		$321K Buy
45,995
+30,295
+193% +$295K ﹤0.01% 2005
2022
Q1 		$237K Sell
15,700
-55,147
-78% -$866K ﹤0.01% 2293
2021
Q4 		$1.55M Buy
+70,847
New +$1.74M ﹤0.01% 2151

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Investments's FDMT Position: Q1 2026 in Review

Two Sigma Investments reduced its 4D Molecular Therapeutics (FDMT) stake by 63% in Q1 2026, selling an estimated $1.86M and leaving 124,317 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Two Sigma Investments first reported a position in FDMT in Q4 2021 and has held it in 17 quarters since. The position peaked at $3.45M in Q1 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Two Sigma Investments held 124,317 shares of 4D Molecular Therapeutics worth $1.16M as of Q1 2026.
  • Two Sigma Investments sold 213,186 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.86M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3153 holding.
  • Two Sigma Investments first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Two Sigma Investments's 4D Molecular Therapeutics position peaked at $3.45M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.